Clinical Report: Significant Elevation of CA19-9 in Ovarian Endometriosis
Background
CA19-9 is primarily a tumor marker associated with pancreaticobiliary and gastrointestinal malignancies. Its elevation in benign gynecological conditions, such as ovarian endometriosis, is rare and can complicate diagnosis.
Data Highlights
No numerical data or trial data presented in the article, which limits the generalizability of the findings.
Key Findings
A 44-year-old female presented with elevated CA19-9 levels (2453.1 U/mL) and pelvic symptoms.
Extensive workup excluded gastrointestinal malignancies, leading to a diagnosis of ovarian endometriosis.
Postoperative endocrine therapy resulted in normalization of CA19-9 levels.
Elevated CA19-9 can occur in benign conditions, necessitating careful differential diagnosis.
Comprehensive clinical evaluation and pathological confirmation are essential for accurate diagnosis.
Clinical Implications
Clinicians should consider benign conditions like ovarian endometriosis when faced with elevated CA19-9 levels in women.
Conclusion
This case highlights the need for awareness of atypical presentations of elevated CA19-9 in benign conditions.
Single-nucleus sequencing of menstrual fluid identified epithelial gene signatures and prioritized five candidate biomarkers that warrant validation in larger studies.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
